Silverarc Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Silverarc Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-30,000	Closed	-$215K	–	87
2025 Q3	$215K	Sell	30,000 -52,023	-63%	-$2.71M	0.03%	79
2025 Q2	$3.87M	Buy	+82,023	New	+$3.34M	0.71%	33
2024 Q1	–	Sell	-50,000	Closed	-$3.02M	–	89
2023 Q4	$3.02M	Buy	+50,000	New	+$2.58M	0.9%	41
2023 Q3	–	Sell	-200,000	Closed	-$10.2M	–	93
2023 Q2	$10.2M	Buy	200,000 +94,250	+89%	+$2.54M	3.16%	10
2023 Q1	$2.26M	Buy	+105,750	New	+$1.78M	0.93%	42
2022 Q1	–	Sell	-131,823	Closed	-$1.3M	–	78
2021 Q4	$1.3M	Sell	131,823 -92,083	-41%	-$915K	0.53%	50
2021 Q3	$2.22M	Sell	223,906 -10,114	-4%	-$101K	1.26%	26
2021 Q2	$2.42K	Buy	234,020 +5,535	+2%	+$56.2K	1.08%	34
2021 Q1	$2.33M	Buy	228,485 +13,414	+6%	+$148K	1.27%	30
2020 Q4	$2.44M	Buy	+215,071	New	+$2.28M	1.42%	25

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Silverarc Capital Management's MLTX Position: Q4 2025 in Review

Silverarc Capital Management sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2025, closing a stake of 30,000 shares — an estimated $215K sold.

Silverarc Capital Management first reported a position in MLTX in Q4 2020 and held it in 10 quarters. The position peaked at $10.2M in Q2 2023. 130 funds tracked by Wall St. Rank hold MLTX as of Q4 2025.

Silverarc Capital Management reported no remaining MoonLake Immunotherapeutics position as of Q4 2025 after selling out during the quarter.
Silverarc Capital Management sold 30,000 MoonLake Immunotherapeutics shares in Q4 2025, an estimated $215K.
Silverarc Capital Management first reported a position in MoonLake Immunotherapeutics in Q4 2020 and held it in 10 quarters.
Silverarc Capital Management's MoonLake Immunotherapeutics position peaked at $10.2M in Q2 2023.
130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2025.

Based on Silverarc Capital Management's 13F filing for Q4 2025, filed 12 Feb 2026.